Ideally, all patients in the European Union should have equal access to safe, efficacious, and high-quality medicines. However, reality is more erratic, as many European citizens are all too familiar with the frustration of limited access to medicines.

Scendea is pleased to share our experience at the 11th annual MIBio conference, a gathering of experts in the fields of biologics formulations and drug delivery. The conference served as a platform for illuminating discussions on the stability of biopharmaceuticals.

This October, Scendea’s Principal Consultant, Ian Waterson, had the pleasure of attending the UK BioIndustry Association (BIA) conference on The Future of UK Regulation: Driving innovation in the Life Sciences.

A growing body of pre-clinical and clinical research has implicated the influence of bacteria on human health which over the last decade led to a flurry of venture capital and biopharma interest.

Micro, small and medium-sized enterprises (SMEs) are valuable sources of pharmaceutical innovation. In 2020, nearly 20% of all human medicines recommended for authorisation were developed by SMEs, with half of these targeting rare diseases.

Biocentury has helped biotech executives and investors make business critical decisions and build larger networks with peers across the innovation ecosystem. To kick of a European tour celebrating the 30th anniversary of the organisation, and in-depth interview with Emer Cooke, executive director of the European Medicines Agency was held in Amsterdam.

Vaccines have been in the spotlight in recent years and are a hot topic. Indeed, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a focus, but other vaccine development has not halted. In the last 12 months alone a number of vaccines have been authorised in the EU and U.S and are presented below and discussed in this short summary.

Scendea were thrilled to attend the two-day Advanced Therapies 2023 Congress, held at ExCel London, on 14 and 15 March. The event is Europe’s largest cell and gene conference and exhibition, and brings together experts in the field of advanced therapy medicinal products (ATMPs) who are at the forefront of efforts aiming to improve patient access to quality, safe and effective cell and gene therapies.

Discover the latest developments in gene therapy, and how CRISPR-Cas Technologies are shaping the future of gene editing, in our new whitepaper, "Off-Target Challenges for Gene Editing". Authored by Scendea's Head of Non-Clinical & Principal Consultant, Dr Angeles Escarti-Nebot and Associate Consultant, David Kidd.